Business Standard

Monkeypox bite: Bavarian Nordic is becoming a 'hot stock' again

Shares in the Danish biotech, which makes the only monkeypox vaccine approved by the US Food and Drug Administration, have gained 69% since hitting a low in early May

Bavarian Nordic
Premium

Analysts covering the stock are also positive, with eight of the nine firms tracked by Bloomberg rating Bavarian Nordic a buy.

Jonas Ekblom & Christian Wienberg | Bloomberg
Bavarian Nordic A/S is having a bit of a meme-stock moment, with retail traders buying up shares in the monkeypox vaccine maker as cases of the virus steadily rise.

Shares in the Danish biotech, which makes the only monkeypox vaccine approved by the US Food and Drug Administration, have gained 69% since hitting a low in early May. At the same time, cases of the virus have jumped from just a handful in Europe at the start of last month to more than 1,200 cases, mostly in men, across the region, as well as in the Americas, the Middle East, and

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 18 2022 | 1:49 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com